Nanobodies: Mini-Antibodies for Diagnostics and Therapeutics
3 Times Sq, New York, NY 10036
The Office of Research Administration welcomes Michael P. Rout, Ph.D., George and Ruby Destevens Professor, Laboratory of Cellular and Structural Biology, The Rockefeller University.
Join us to learn about the latest advancements in antibody technology, particularly in the context of diagnostics and therapeutics. Some key highlights:
- Introduction to Nanobodies: Nanobodies are small single-domain antibodies derived from camelids that can be targeted with high specificity against almost any antigen.
- Innovative Technology: We developed a mass spectrometry-based technology that overcomes the limitations of some other screening methods, enabling the rapid production of large repertoires of readily expressible recombinant nanobodies against any given antigen with very high affinities and specificities.
- COVID-19 and Beyond: During the COVID-19 pandemic, we identified classes of nanobodies that have exceptional biophysical characteristics and unique and orthogonal mechanisms for neutralizing SARS-CoV-2, and that maintain their neutralizing efficacy against current variants.
- Broad Applications: We are now using our pipeline to generate repertoires of nanobodies against other targets of biomedical importance, enabling use in CAR-T therapeutics, treatment or diagnosis of several cancer types, and various infectious diseases.